What Are the Clinical Trial Phases Required by CDE in China for a New Biologic?

A comprehensive guide for foreign biotech companies navigating CDE clinical trial requirements for biologic drug development in China.

Introduction

China’s Center for Drug Evaluation (CDE), operating under the National Medical Products Administration (NMPA), has established a comprehensive clinical trial framework for biologic drugs that aligns closely with international standards while incorporating China-specific requirements. For foreign biotech companies developing biologic therapies, understanding the clinical trial phases mandated by CDE is essential for successful drug registration in the Chinese market. This guide provides a detailed walkthrough of the clinical trial phases required by CDE for new biologics, from Investigational New Drug (IND) application through post-marketing studies, including timelines, documentation requirements, and strategic considerations for foreign sponsors in 2025–2026.

Regulatory Foundation: CDE’s Clinical Trial Framework for Biologics

The CDE’s requirements for biologic clinical trials are rooted in the Drug Administration Law, the Measures for Drug Registration (2020), and the Provisions for Drug Clinical Trial Management (GCP, 2020 revision). Since China became a full member of the International Council for Harmonisation (ICH) in 2017, the CDE has progressively adopted ICH guidelines including ICH E6 (Good Clinical Practice), ICH E8 (General Considerations for Clinical Trials), and ICH E9 (Statistical Principles). Biologics, defined as products derived from living organisms including monoclonal antibodies, recombinant proteins, gene therapies, cell therapies, and vaccines, generally require the same four-phase clinical trial structure as chemical drugs, though with specific considerations for immunogenicity, pharmacokinetics, and manufacturing consistency.

Pre-IND Phase: The Critical Preparation Stage

Before initiating any clinical trial in China, foreign biotech companies must first complete the IND application process with CDE. The pre-IND phase involves several critical steps:

• IND application preparation: Compilation of a comprehensive dossier including pharmaceutical research data, pharmacological and toxicological studies (pharmacokinetics, pharmacodynamics, acute and chronic toxicity, reproductive toxicity, genotoxicity, carcinogenicity for chronic-use biologics, and local tolerance studies), manufacturing process information, and quality control specifications.
• Pre-IND consultation meeting: Foreign companies are strongly encouraged to request a pre-IND consultation meeting with CDE to discuss clinical trial design, patient population, dosage selection, and endpoint selection. The CDE typically responds to such requests within 30 working days and schedules the meeting within 60 working days.
• Ethics committee approval: Clinical trial protocols must be reviewed and approved by an institutional ethics committee (EC) at each proposed trial site before enrollment can begin.
• Clinical trial application (CTA) registration: Submission of the CTA through the CDE’s online platform, including the clinical trial protocol, investigator’s brochure, informed consent form, and case report forms.

The CDE has 60 working days (about 3 calendar months) to review the IND application and either grant approval, issue a clinical trial waiver, or raise questions. If no questions are raised within 60 working days, the trial is deemed approved — a silent approval mechanism that has streamlined the process significantly since its introduction in 2018. For priority review applicants, this timeline is reduced to 30 working days.

Phase I Clinical Trials: First-in-Human Studies in China

Phase I trials for biologics in China evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of the new biologic in human subjects. The CDE requires Phase I trials to be conducted in accordance with ICH guidelines, with specific considerations:

• Study population: Typically 20–80 healthy volunteers for most biologics, though patient populations may be used for highly toxic biologics (e.g., oncology immunotherapies) or when the biologic’s mechanism of action makes healthy volunteer studies inappropriate.
• Dose escalation: Single ascending dose (SAD) and multiple ascending dose (MAD) studies are standard. The starting dose must be supported by adequate non-clinical safety data following ICH S6 (Preclinical Safety Evaluation of Biotechnology-Derived Pharmaceuticals) and S9 (Nonclinical Evaluation for Anticancer Pharmaceuticals).
• Special requirements for biologics: Immunogenicity assessment is mandatory in Phase I — anti-drug antibody (ADA) and neutralizing antibody (NAb) assays must be developed and validated. PK assays for biologics typically use ligand-binding methods (ELISA, MSD, Gyrolab) rather than LC-MS/MS common for small molecules.
• Duration: Phase I trials in China typically take 6–12 months depending on the complexity of the dosing regimen and the number of cohorts.
• Ethnic sensitivity evaluation: For biologics developed primarily in non-Chinese populations, the CDE may require ethnicity comparison data to assess whether China-specific dose adjustments are needed before proceeding to Phase II.

Phase II Clinical Trials: Dose-Finding and Proof of Concept

Phase II trials in China provide crucial data on the biologic’s efficacy, optimal dosing, and safety profile in the target patient population. CDE requirements for Phase II biologics trials include:

• Study population: 100–500 patients with the target indication, typically at 3–15 sites across China.
• Study design: Randomized, controlled, and often double-blind designs are preferred. The CDE has shown increasing willingness to accept adaptive trial designs for biologics, including seamless Phase I/II or Phase II/III designs for innovative therapies.
• Dose-ranging: At least two to three dose levels are recommended, including the expected therapeutic dose, a lower sub-therapeutic dose, and a higher dose for safety margin assessment.
• Duration: Phase II trials in China typically take 12–24 months, including enrollment, treatment, follow-up, and data analysis. Enrollment timelines in China can be faster than in Western countries due to the large patient pool, but regulatory submission timelines are similar.
• Interim analysis: The CDE allows interim analyses in Phase II trials to support early termination for futility, safety concerns, or overwhelming efficacy, provided the protocol clearly specifies the analysis plan and stopping rules.

Phase III Clinical Trials: Confirmatory Pivotal Studies

Phase III trials are the cornerstone of NMPA drug registration for biologics. These confirmatory studies must provide robust evidence of the biologic’s safety and efficacy to support marketing authorization. CDE requirements for Phase III trials include:

• Study population: 500–5,000 patients, typically at 10–50 sites across China. For foreign biologics seeking NMPA approval based on global Phase III data, the CDE may require a China-specific bridging study or at least a sufficient Chinese patient subset within the global trial.
• Endpoints: Clinically meaningful endpoints are required. For oncology biologics, overall survival (OS) remains the gold standard, though progression-free survival (PFS) and objective response rate (ORR) may be accepted for certain indications. Surrogate endpoints require CDE pre-approval.
• Multi-regional clinical trials (MRCTs): Under ICH E17, foreign companies can include Chinese sites in global Phase III MRCTs. The CDE requires that the China cohort is large enough to demonstrate that the treatment effect in Chinese patients is consistent with the overall population — typically 15–20% of the global sample size or a statistically justified minimum.
• Duration: Phase III trials typically take 24–48 months, making them the longest phase of clinical development. However, the CDE’s acceptance of MRCT data can significantly reduce timelines for foreign companies that already have global Phase III programs underway.
• Data quality requirements: The CDE has increasingly strict requirements for electronic data capture (EDC), source data verification, and risk-based monitoring. Foreign companies must ensure their clinical data management systems comply with China’s data localization requirements.

Phase IV Clinical Trials: Post-Marketing Studies (Optional)

Phase IV trials are conducted after the biologic has received NMPA marketing approval. While not always mandatory, Phase IV studies are commonly required by the CDE through the drug registration certificate’s conditions — particularly for products that received conditional approval based on surrogate endpoints. Phase IV requirements include:

• Post-marketing surveillance: Mandatory for all biologic drugs in China under the adverse drug reaction (ADR) reporting system. Foreign companies must establish a pharmacovigilance system in China.
• Conditional approval follow-up: If the biologic received conditional NMPA approval, the company must complete the confirmatory Phase IV study within the specified timeframe (typically 3–5 years) and submit results to CDE for conversion to full approval.
• Real-world evidence: The CDE is increasingly accepting real-world evidence (RWE) from post-marketing studies to support label extensions, new indication approvals, and safety monitoring.
• Immunogenicity follow-up: Long-term immunogenicity monitoring is often required for biologics to detect late-onset ADA responses.

Special Trial Designs and Pathways for Biologics

Foreign biotech companies developing innovative biologics can leverage several special pathways offered by CDE:

• Breakthrough Therapy Designation (BTD): For biologics demonstrating substantial improvement over existing therapies for serious conditions. BTD provides intensive CDE guidance, rolling review, and potential for smaller or shorter pivotal trials.
• Conditional Approval: Allows earlier market access based on surrogate endpoints for drugs addressing unmet medical needs, with mandatory post-marketing confirmatory trials.
• Priority Review: Shortens the NMPA review timeline to 6–12 months for chemical drugs and 12–18 months for biologics (including drug registration review).
• Expanded Access: For patients with life-threatening conditions who cannot enroll in clinical trials, expanded access programs are available under CDE guidelines.
• Stem cell and gene therapy special provisions: The CDE has specific guidelines for cell and gene therapy products, which may involve modified clinical trial requirements including extended long-term follow-up for gene-editing therapies.

Key Differences: Clinical Trials in China vs. US/EU for Biologics

Foreign biotech companies should be aware of the following China-specific clinical trial requirements:

• Ethnic sensitivity data: The CDE places greater emphasis on ethnic sensitivity analysis than FDA or EMA, requiring data on how genetic, dietary, and environmental factors may affect the biologic’s safety and efficacy in Chinese patients.
• IND 60-day silent approval: Unlike the FDA’s 30-day IND review period (with explicit approval required), China’s 60-working-day silent approval mechanism means the trial can proceed automatically if CDE raises no objections — a unique feature that can accelerate timelines.
• Local clinical trial registration: All clinical trials in China must be registered on the Chinese Clinical Trial Registry (ChiCTR) before enrollment begins, separate from ClinicalTrials.gov registration.
• Biospecimen export restrictions: Human genetic resources regulations require approval from the Ministry of Science and Technology for exporting or sharing human biological samples collected in Chinese clinical trials.
• Data localization: Clinical trial data collected in China must be stored on servers located within mainland China, with strict requirements for cross-border data transfers under the Personal Information Protection Law (PIPL).

Timeline Summary: From IND to NMPA Approval

For a foreign biotech company developing a new biologic for the Chinese market, the total timeline from IND submission to NMPA marketing approval is typically:

• Pre-IND phase: 3–6 months (consultation, dossier preparation, ethics approval)
• IND review: 3 months (60 working days for standard review)
• Phase I: 6–12 months
• Phase II: 12–24 months
• Phase III: 24–48 months
• NDA review: 6–18 months for biologics (12 months standard, 6–9 with priority review)

Total estimated timeline: 4–8 years for a complete clinical development program in China. However, for biologics that have already completed Phase I–II trials abroad and leverage MRCT Phase III data, the total timeline can be compressed to 2–4 years.

Conclusion

The CDE requires comprehensive clinical trial data across all four phases for new biologic drug approval in China — Phase I safety and pharmacokinetics, Phase II dose-finding and proof-of-concept, Phase III confirmatory efficacy and safety, and Phase IV post-marketing surveillance. For foreign biotech companies, the key to navigating these requirements successfully lies in early engagement with CDE through pre-IND consultation meetings, strategic use of MRCT designs to include Chinese sites in global trials, rigorous adherence to China-specific GCP and data localization requirements, and careful planning of immunogenicity and ethnic sensitivity studies. With China’s full ICH alignment and the CDE’s increasingly efficient review processes, conducting clinical trials in China has become both more predictable and more attractive for foreign biotech companies developing innovative biologic therapies.

This article is for informational purposes only and does not constitute legal or regulatory advice. Clinical trial requirements and timelines are based on current CDE regulations as of 2025–2026 and may be subject to change. Foreign companies should consult qualified regulatory affairs and clinical operations professionals for advice specific to their biologic product.